Posted by Michael Wonder on 24 Sep 2018
MicuRx announces receipt of FDA’s QIDP and fast track designations for contezolid and contezolid acefosamil
21 September 2018 - MicuRx Pharmaceuticals today announced the receipt of the qualified infectious disease product classification and grant of fast track status by the U.S. FDA for contezolid (MRX-I) and its pro-drug contezolid acefosamil (MRX-4) for the treatment of acute bacterial skin and skin structure infections.
Contezolid and contezolid acefosamil are next-generation oxazolidinone agents with notably reduced hematologic toxicity compared to earlier antibiotics of this class, such as linezolid, while maintaining the excellent therapeutic efficacy of the class. Contezolid and contezolid acefosamil are active against multidrug-resistant, Gram-positive organisms, including MRSA and VRE, which are categorized as a high threat by the World Health Organisation.
